Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Melan-A VLP vaccine

A vaccine consisting of the melanocyte differentiation antigen Melan A (also called MART-1) encapsulated in noninfectious virus-like particles (VLPs) with potential immunostimulating and antineoplastic activities. Upon administration, Melan-A VLP vaccine may stimulate the immune system to exert a specific cytotoxic T lymphocyte (CTL) response against tumor cells expressing the Melan A antigen, resulting in tumor cell lysis. Melan A is upregulated in most melanomas. VLPs stimulate the immune system and promotes the CTL response.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search